CL
SMMT icon

CSS LLC’s Summit Therapeutics SMMT Stock Holding History

CSS LLC’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,000
Closed -$15.6K – 987
2024
Q2 		$15.6K Buy
+2,000
New +$10.8K ﹤0.01% 827
2023
Q4 		– Sell
-500
Closed -$935 – 913
2023
Q3 		$935 Sell
500
-2,000
-80% -$3.81K ﹤0.01% 801
2023
Q2 		$6.28K Buy
2,500
+1,100
+79% +$2.01K ﹤0.01% 854
2023
Q1 		$2.45K Buy
+1,400
New +$3.82K ﹤0.01% 705

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

CSS LLC's SMMT Position: Q1 2025 in Review

CSS LLC sold out of Summit Therapeutics (SMMT) in Q1 2025, closing a stake of 27,314 shares — an estimated $487K sold.

CSS LLC first reported a position in SMMT in Q1 2023 and held it in 8 quarters. The position peaked at $915K in Q1 2023. 212 funds tracked by Wall St. Rank hold SMMT as of Q1 2025.

  • CSS LLC reported no remaining Summit Therapeutics position as of Q1 2025 after selling out during the quarter.
  • CSS LLC sold 27,314 Summit Therapeutics shares in Q1 2025, an estimated $487K.
  • CSS LLC first reported a position in Summit Therapeutics in Q1 2023 and held it in 8 quarters.
  • CSS LLC's Summit Therapeutics position peaked at $915K in Q1 2023.
  • 212 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2025.

Based on CSS LLC's 13F filing for Q1 2025, filed 15 May 2025.